Abbott Laboratories (NYSE:ABT) on Thursday posted upbeat first-quarter earnings but revised its 2026 earnings outlook below expectations.
The global healthcare company reported quarterly sales of $11.16 billion, slightly beating the consensus of $10.99 billion. Abbott reported adjusted earnings of $1.15 per share, beating the Wall Street estimate of $1.14 and management guidance of $1.12-$1.18 per share.
The global healthcare company on Thursday said it expects the second quarter of 2026 adjusted earnings of $1.25-$1.31, below the consensus of $1.37. Abbott lowered its fiscal 2026 adjusted earnings from $5.55-$5.80 per share to $5.38-$5.58 per share compared to the Wall Street consensus of $5.62.
The updated guidance includes 20 …
This post was originally published here
